KRTL ASIA CO. LTD.
KRTL Asia has a strategic purpose which encompasses many benefits and are not limited to:
-
Meeting Domestic Government requirements for R&D companies to operate, obtain MFDS approvals, access to Government facilities, obtain strategic development grants, and direct access to nonprofit organizations in Korea
-
KRTL Asia can potentially meet required guidelines to become a Publicly Traded company in Asia
-
KRTL Asia has the possibility of 100 percent ownership of its IP to better protect its patents
-
KRTL Asia benefits form the Korean territory credibility with its neighbors and be able to collaborate with other Asian countries like Japan for additional R&D development
-
Creates government opportunities for grants, access to Government facilities and other domestic nonprofit partnerships
-
Can be the first to introduce and register Cannabis seeds in Korea with government approval and create a future CBD seed bank in Asia
-
Brings opportunity to develop and distribute products within tariff free zone territories
-
KRTL Biotech the parent company owns 49 percent of KRTL Asia with the authority to negotiate favorable opportunities
-
Board members of KRTL Biotech Inc sit on KRTL Asia
-
KRTL Asia can benefit by having access to proprietary technologies and R&D opportunities in the lucrative Korean cosmetics industries
-
Headquarters for all future treatment facilities Inside Asian boundaries. KRTL Asia has a market focused on VIP clients inside Korea and other Asian countries for its planned future facilities and products
-
C3 Co. Ltd. signed an exclusive manufacturing agreement with KRTL, they are FDA class 2 approved and CGMP manufacturer in Korea
-
JBF Jeonnam Bioindustry Foundation Center of Natural Resources Research has signed MOU with KRTL Asia, KRTL Biotech, and KRTL Canada
-
With JBF we can now add over 20 additional ailments such skin diseases and include veterinary medicines to our roster of research

Kyong Lae (Kai) Kim
Founder/ CEO KRTL Asia


A Wholly Owned Subsidiary of QUEENCH, Inc. OTC: QENC
